With say $150k per patient, that would translate about 2500 patients. I heard annual capacity able to serve 5000 patients. That means double that mcap?
Without the side effects, I would foresee demand supply issues. Better supply is ready to meet demand.
Is that why we have to wait this long to also make sure supply is ready besides waiting for data to mature?
The book was written for Dendreon; chapters include various clinical trials, approval, near bankruptcy, being bought out by several companies, and current sales. It's parent now is a Chinese conglomerate. Can't wait to get to the next chapter of NWBO's DCVAX saga about TLD, hopefully in a month or 2.